To understand the synergistic effects of combining RT with the PD-1/PD-L1 blockade, dynamic RT-induced alterations in tumor immune status and blood-borne biomarkers in relation to PD-1/PD-L1 expression must be explored. The gene discussed is CD274; the disease is neoplasm.